No Commingling of Technology Sample Clauses

No Commingling of Technology. The terms of this Agreement do not preclude Customer from developing a product substantially compatible with format supported by the Software, where such product does not incorporate the Software (a “Clone Product”); however, if Customer engages in Clone Product development, it shall ensure that there is no use of the Confidential Information in the design and development of such Clone Product. This paragraph shall survive expiration or termination of this Agreement. Datalogics agrees: • to deliver the Software to Customer in a timely manner after approving the evaluation. • to provide question and answer support services on non-holiday weekdays from 0700 hours to 1700 hours Central Time. Out of hours requests should be submitted via electronic mail and will be addressed on the next business day. Customer agrees: • to destroy the Software upon expiration of this Agreement, and return a signed Attachment 1 - Certificate of Destruction on or before specified return date. • not to transfer, sell, assign, sublicense, pledge, or otherwise dispose of, encumbrance upon or against, any interest in the Software.
Sample 1Sample 2
AutoNDA by SimpleDocs
No Commingling of Technology. TRX SHALL ENSURE THAT THERE IS NO USE OF THE LICENSED SOFTWARE SOURCE CODE IN THE DESIGN AND DEVELOPMENT OF COMPETITIVE PRODUCTS. IN FURTHERANCE OF SUCH REQUIREMENT, TRX SHALL ENSURE THERE IS NO SHARING WITH SUCH DEVELOPMENT ON ANY OF THE FOLLOWING: (I) DESIGN DOCUMENTS OR SCHEMATICS SUPPLIED BY SABRE; (II) SOFTWARE SOURCE CODE OR OTHER CONFIDENTIAL INFORMATION; (III) ANY FACILITIES (INCLUDING, BUT NOT LIMITED TO, COMPUTER SYSTEMS AND NETWORK STORAGE DEVICES); OR (IV) PERSONNEL WITH ACCESS TO ANY OF (I)-(III) ABOVE. TRX SHALL ENSURE THAT ALL AUTHORIZED EMPLOYEES WHO HAVE HAD PREVIOUS ACCESS TO SOFTWARE SOURCE CODE WILL BE PRECLUDED FOR A PERIOD OF TWELVE (12) MONTHS AFTER THEIR LATEST ACCESS TO SUCH SOFTWARE SOURCE CODE FROM BEING EMPLOYED IN ANY COMPETITIVE PRODUCT DEVELOPMENT BY OR FOR TRX.
Sample 1Sample 2
No Commingling of Technology. The terms of this Section do not preclude SEC from developing a Clone Product; however, if SEC engages in such Clone Product development during the term of this Agreement, it shall ensure that there is no use of the Adobe Information in the design and development of Clone Products. In furtherance of such requirement, SEC shall ensure there is no sharing with such Clone Product development any of the following: (i) design documents or schematics supplied by Adobe; (ii) Adobe Support Information or other information based upon or derived from the Adobe Support Information; (iii) any facilities (including, but not limited to, computer systems and network storage devices); or (iv) personnel with access to any of (i)-(iii) above. SEC shall ensure that all Authorized Employees and Authorized Contractors who have had previous access to Adobe Support Information will be precluded for a period of twelve (12) months after their latest access to such Adobe Support Information from being employed in any Clone Product development (either internally or externally) by or for SEC. "Employment in any Clone Product development" shall be defined as having direct access to, or producing any specifications, documentation, or source code for, components of a Clone Product. SEC shall further ensure that each such employee or contractor shall, concurrent with the commencement of work on such Clone Product development within SEC, sign a written affirmation to SEC which states that each such employee or contractor (a) has neither retained nor had access for a minimum period of twelve (12) months to any Adobe Support Information, and (b) will not utilize, or facilitate use of, any Adobe Support Information in such Clone Product development. This prohibition relating to Clone Product development shall apply equally to raster-output devices, to display or screen output devices, or to any other peripheral devices. Notwithstanding the foregoing, any Authorized Employee or Authorized -------------------------------------------------------------------------------- Draft #6 (March 28, 2000) Page 31 Initials: PSIP___; SEC ___ Contractor who has only received access to (i) documentation (but not including the Adobe Certification Test Suites) or any source code documentation) or (ii) object code (but no source code) contained in the Adobe Support Information shall be exempted from such requirement.
Sample 1
No Commingling of Technology. Supplier shall ensure that there is no use of the Confidential Information in the development of any products or software by Supplier except in connection with the Services. In furtherance of this requirement, Supplier shall ensure that there is no (a) disclosure of any Confidential Information or other information based upon or derived from the Confidential Information to any participant in any development project outside the Services; or (b) participation in development of any product or software similar in features or functions to Chordiant’s software (“Similar Products”) by any person with access to such Confidential Information. Supplier shall ensure that all EDC Personnel who have had previous access to Confidential Information will be precluded for a period of twelve (12) months after [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. their latest access to such Confidential Information from being employed in any development of Similar Products (either internally or externally) by or for Supplier. “Employment in the development of Similar Products” means having direct access to, or producing any specifications, documentation, or source code for, components of a Similar Product. Supplier shall further ensure that each such employee signs, before beginning work on any Similar Product within Supplier, a written affirmation to Supplier on a form provided by Supplier which states that the employee (i) has neither retained nor had access for a minimum period of twelve (12) months to any Confidential Information, and (ii) will not utilize, or facilitate use of, any Confidential Information in such development.
Sample 1
No Commingling of Technology. The terms of this Paragraph do not preclude OEM Customer from developing a Clone Product; however, if OEM Customer engages in such Clone Product development during the term of this Agreement, it shall ensure that there is no use of the Adobe Information in the design and development of Clone Products.
Sample 1

Related to No Commingling of Technology

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Joint Technology The Parties agree that, in order to effectuate the provisions of Section 4.4.2, subject to any exclusive licenses granted hereunder, (a) the non-use provisions of this Article 9 shall not apply to each Party’s use of Joint Technology, and (b) each Party may disclose the Joint Technology to Third Parties who are under terms of confidentiality no less strict than those contained in this Agreement.

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

  • No Infringement of Third Party IP Rights The Company has never infringed (directly, contributorily, by inducement or otherwise), misappropriated or otherwise violated or made unlawful use of any Intellectual Property Right of any other Person. No Owned Company Software and, to the Knowledge of the Company, no Licensed Company Software infringes, violates or makes unlawful use of any Intellectual Property Right of, or contains any Intellectual Property misappropriated from, any other Person. Without limiting the generality of the foregoing:

  • Licensed Technology The term "Licensed Technology" shall mean the ------------------- Licensed Patents, plus all improvements thereto developed by Licensor, and all related data, know-how and technology.

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Third Party Technology The Company makes use of third party technology to collect information required for traffic measurement, research, and analytics. Use of third party technology entails data collection. We therefore would like to inform clients the Company enables third parties to place or read cookies located on the browsers of users entering the Company’s domain. Said third parties may also use web beacons to collect information through advertising located on the Company’s web site. Please note that you may change your browser settings to refuse or disable Local Shared Objects and similar technologies; however, by doing so you may be disabling some of the functionality of Company’s services.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

Time is Money Join Law Insider Premium to draft better contracts faster.